公开(公告)号：US08025881B2

公开(公告)日：2011-09-27

申请号：US12374473

申请日：2007-07-19

申请人： Toshio Doi ,  Hideharu Abe ,  Naoshi Fukushima ,  Hitoshi Tai ,  Takakazu Mizuno ,  Masahiko Kinosaki

发明人： Toshio Doi ,  Hideharu Abe ,  Naoshi Fukushima ,  Hitoshi Tai ,  Takakazu Mizuno ,  Masahiko Kinosaki

IPC分类号： A61K39/395 ,  C12N5/12 ,  C07K16/00 ,  C07K16/18 ,  C07K16/22

CPC分类号： C07K16/22 ,  A61K2039/505 ,  C07K2317/76

摘要： When an anti-human BMP antibody was added to cells of an immortalized human mesangial cell line cultured in the presence of human BMP, the anti-human BMP antibody significantly suppressed the production of type IV collagen in mesangial cells. A number of signaling pathways are involved in abnormal proliferation of type IV collagen. It was therefore completely unpredictable whether merely blocking the BMP signal would indeed suppress the abnormal proliferation of type IV collagen. However, for the first time, the present inventors demonstrated that anti-BMP antibodies are very effective in suppressing the abnormal proliferation of type IV collagen. Thus, anti-BMP antibodies can be used as novel therapeutic agents for kidney diseases associated with abnormal proliferation of the mesangial matrix.

摘要翻译： 当将抗人BMP抗体加入到在人BMP存在下培养的永生化人肾小球系膜细胞的细胞中时，抗人BMP抗体显着抑制肾小球系膜细胞中IV型胶原的产生。 许多信号通路涉及IV型胶原异常增殖。 因此，完全不可预测的是，只是阻断BMP信号将确实抑制IV型胶原蛋白的异常增殖。 然而，本发明人第一次证明抗BMP抗体在抑制IV型胶原蛋白的异常增殖方面非常有效。 因此，抗BMP抗体可用作与肾小球系膜基质异常增殖相关的肾脏疾病的新型治疗剂。

公开(公告)号：US20100003245A1

公开(公告)日：2010-01-07

申请号：US12374473

申请日：2007-07-19

申请人： Toshio Doi ,  Hideharu Abe ,  Naoshi Fukushima ,  Hitoshi Tai ,  Takakazu Mizuno ,  Masahiko Kinosaki

发明人： Toshio Doi ,  Hideharu Abe ,  Naoshi Fukushima ,  Hitoshi Tai ,  Takakazu Mizuno ,  Masahiko Kinosaki

IPC分类号： A61K39/395 ,  C12N5/06 ,  C07K16/18

CPC分类号： C07K16/22 ,  A61K2039/505 ,  C07K2317/76

摘要： When an anti-human BMP antibody was added to cells of an immortalized human mesangial cell line cultured in the presence of human BMP, the anti-human BMP antibody significantly suppressed the production of type IV collagen in mesangial cells. A number of signaling pathways are involved in abnormal proliferation of type IV collagen. It was therefore completely unpredictable whether merely blocking the BMP signal would indeed suppress the abnormal proliferation of type IV collagen. However, for the first time, the present inventors demonstrated that anti-BMP antibodies are very effective in suppressing the abnormal proliferation of type IV collagen. Thus, anti-BMP antibodies can be used as novel therapeutic agents for kidney diseases associated with abnormal proliferation of the mesangial matrix.

摘要翻译： 当将抗人BMP抗体加入到在人BMP存在下培养的永生化人肾小球系膜细胞的细胞中时，抗人BMP抗体显着抑制肾小球系膜细胞中IV型胶原的产生。 许多信号通路涉及IV型胶原异常增殖。 因此，完全不可预测的是，只是阻断BMP信号将确实抑制IV型胶原蛋白的异常增殖。 然而，本发明人第一次证明抗BMP抗体在抑制IV型胶原蛋白的异常增殖方面非常有效。 因此，抗BMP抗体可用作与肾小球系膜基质异常增殖相关的肾脏疾病的新型治疗剂。